Teva Pharmaceutical Industries

Overview

Overview

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. Founded in 1901 as a small wholesale business, Teva has grown to become one of the world's largest generic drug manufacturers and a significant player in the specialty pharmaceuticals market["@tevawebsite"]. With operations in more than 60 countries and a portfolio of over 3,500 products, Teva plays a critical role in providing affordable medications for neurological disorders, including [Parkinson's disease](/diseases/parkinsons-disease) and [Huntington's disease](/diseases/huntingtons)[@teva2024].

The company's neuroscience portfolio spans both generic and specialty medications, making it a major supplier of essential CNS treatments globally. Teva's generic versions of [levodopa](/therapeutics/levodopa), pramipexole, and other Parkinson disease therapies ensure patient access to affordable treatments, while its specialty pipeline includes novel mechanisms targeting movement disorders["@tevapipe"].

Company Profile

| Attribute | Detail |
|-----------|--------|
| Headquarters | Petah Tikva, Israel |
| Founded | 1901 |
| Ticker | TEVA (NYSE, TASE) |
| CEO | Francesco Gattrone (2024-present) |
| Employees | ~37,000 |
| Market Cap | ~$10 billion (2024) |
| Revenue (2023) | ~$16 billion |
| Focus Areas | Generic Medicines, Specialty Medicines, Over-the-Counter (OTC) |

Teva operates through three main divisions:

• Generic Medicines: The world's largest generic pharmaceutical company, producing over 1,000 generic products
• Specialty Medicines: Focus on specialty products in CNS, oncology, and respiratory
• Over-the-Counter (OTC): Consumer health products

Neuroscience Portfolio

Teva has a significant presence in the central nervous system (CNS) space through both generic and specialty medications that address movement disorders, migraine, and other neurological conditions[@parkinson].

Generic CNS Products

Teva manufactures generic versions of many important CNS drugs, ensuring broad patient access to essential neurological medications[@genericparket]:

| Drug | Brand Equivalent | Indication |
|------|-----------------|------------|
| Levodopa/Carbidopa | Sinemet | [Parkinson's disease](/diseases/parkinsons-disease) |
| Pramipexole | Mirapex | [Parkinson's disease](/diseases/parkinsons-disease) |
| Ropinirole | Requip | [Parkinson's disease](/diseases/parkinsons-disease) |
| Gabapentin | Neurontin | Epilepsy, neuropathic pain |
| Pregabalin | Lyrica | Epilepsy, neuropathic pain |
| Sertraline | Zoloft | Depression |
| Escitalopram | Lexapro | Depression |
| Quetiapine | Seroquel | Schizophrenia |
| Aripiprazole | Abilify | Schizophrenia, bipolar |
| Clonazepam | Klonopin | Seizures, anxiety |

The generic [levodopa/carbidopa](/therapeutics/levodopa) combination remains the gold standard for [Parkinson's disease](/diseases/parkinsons-disease) treatment, and Teva's generic versions ensure this essential therapy remains affordable and accessible globally[@levodopa].

Specialty CNS Products

Teva's specialty pipeline focuses on novel mechanisms for unmet needs in movement disorders and migraine[@deutetrabenazine]:

| Drug | Brand Name | Indication | Mechanism | Status |
|------|------------|------------|-----------|--------|
| Deutetrabenazine | Austedo | Huntington's disease chorea | VMAT2 inhibitor | Approved (2017) |
| Deutetrabenazine | SD-809 | Tardive dyskinesia | VMAT2 inhibitor | Approved (2023) |
| Fremanezumab | Ajovy | Migraine prevention | CGRP monoclonal antibody | Approved (2018) |
| TEV-247 | — | Parkinson's disease | A2A adenosine receptor antagonist | Phase 2 |
| TEV-385 | — | ALS | SOD1 antisense oligonucleotide | Phase 1 |

Deutetrabenazine (Austedo/SD-809)

Deutetrabenazine represents a significant advancement in the treatment of hyperkinetic movement disorders. This novel formulation uses deuterium-substituted tetrabenazine to improve pharmacokinetics and reduce dosing frequency while maintaining efficacy[@deutetrabenazine].

Mechanism of Action

Deutetrabenazine works by reversibly inhibiting VMAT2 (vesicular monoamine transporter 2), which is responsible for packaging monoamines—including dopamine—into synaptic vesicles. In conditions like Huntington's disease and tardive dyskinesia, excessive dopaminergic signaling in the striatum leads to involuntary movements. By modulating VMAT2, deutetrabenazine reduces available dopamine without causing complete depletion[@vmattarget].

The deuterium substitution provides several advantages:

• Reduced metabolic variability: Deuterium slows hepatic metabolism, providing more consistent plasma levels
• Twice-daily dosing: Improved pharmacokinetics allow for less frequent dosing vs. tetrabenazine
• Better tolerability: Lower peak plasma concentrations reduce side effects

Clinical Data

The KARMMA trials demonstrated:

• 40-50% reduction in chorea scores vs. placebo[@deutetrabenazine]
• Significant improvement in timed motor tasks
• Low rates of depression and suicidality (concerns with earlier VMAT2 inhibitors)
• FDA approval in 2017 for Huntington's disease chorea and 2023 for tardive dyskinesia

Fremanezumab (Ajovy) and CGRP Inhibition

Fremanezumab is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a key neuropeptide involved in migraine pathophysiology[@cgrp].

Clinical Profile

• Indications: Episodic and chronic migraine prevention
• Dosing: Monthly (225 mg) or quarterly (675 mg) subcutaneous injection
• Efficacy: Reduces migraine days by approximately 50% in responders
• Target: CGRP ligand — blocks the final common pathway of migraine pain

Pipeline Programs

TEV-247: A2A Adenosine Receptor Antagonist

TEV-247 is in Phase 2 development for [Parkinson's disease](/diseases/parkinsons-disease). Adenosine A2A receptors are highly expressed in the basal ganglia, particularly in the striatum, where they modulate dopaminergic signaling. A2A antagonists like istradefylline (Nourianz) have shown efficacy as adjunct therapy to levodopa.

Rationale: A2A antagonists may provide:

• Reduced "off" time in advanced Parkinson's
• Anti-dyskinetic potential
• Neuroprotective effects through anti-inflammatory mechanisms

TEV-385: SOD1 ASO for ALS

TEV-385 is an antisense oligonucleotide targeting SOD1 mutations that cause approximately 20% of familial ALS. Similar to the FDA-approved tofersen (Qalsody), this approach aims to reduce mutant SOD1 protein production.

Strategic Partnerships

Teva maintains strategic partnerships to enhance its neuroscience capabilities:

| Partner | Focus Area | Details |
|---------|-----------|---------|
| Almirall | Dermatology | Multi-product collaboration |
| Lonza | Manufacturing | Biologics manufacturing |
| MediGene | CNS pipeline | Development partnerships |
| Various academic institutions | Research | Clinical trial collaborations |

Market Position and Competition

Teva occupies a unique position in the pharmaceutical landscape:

Generic Leadership: Teva is the #1 generic pharmaceutical company globally, with significant market share in:

• Generic levodopa combinations (40%+ US market)
• Generic dopamine agonists (30%+ US market)
• Generic antiepileptics (25%+ US market)

• AbbVie (Austedo vs. Ingrezza - VMAT2)
• Eli Lilly/AbbVie (CGRP antibodies)
• Biogen/Ionis (ASO for ALS)
• PharmaNord/Roche (other movement disorder therapies)

Impact on Neurodegenerative Disease Care

Teva's contributions to neurodegenerative disease care are substantial:

Financial Performance

Teva's neuroscience products represent a significant portion of specialty revenue:

• Austedo: Over $1 billion in annual sales (growing 20%+ annually)
• Ajovy: Approximately $300 million in annual sales
• Generic CNS: Approximately $2 billion annually

Future Directions

Teva's neuroscience strategy focuses on:

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
• [Huntington's Disease](/diseases/huntingtons)
• [Movement Disorders](/therapeutics/movement-disorder-treatments)](/therapeutics)
• [Migraine Treatments](/therapeutics/migraine-treatments)](/therapeutics)
• [Levodopa](/therapeutics/levodopa)](/therapeutics)
• [VMAT2 Inhibitors](/therapeutics/vmat2-inhibitors)

References